NxStage Medical, Inc. (NXTM) Expected to Announce Quarterly Sales of $108.07 Million

Wall Street brokerages expect NxStage Medical, Inc. (NASDAQ:NXTM) to report sales of $108.07 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for NxStage Medical’s earnings, with the lowest sales estimate coming in at $106.30 million and the highest estimate coming in at $109.84 million. NxStage Medical posted sales of $97.30 million during the same quarter last year, which would indicate a positive year over year growth rate of 11.1%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 14th.

On average, analysts expect that NxStage Medical will report full-year sales of $432.81 million for the current fiscal year, with estimates ranging from $429.70 million to $435.91 million. For the next financial year, analysts anticipate that the firm will report sales of $467.80 million, with estimates ranging from $467.30 million to $468.30 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for NxStage Medical.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Tuesday, August 7th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%. The company had revenue of $106.97 million during the quarter, compared to the consensus estimate of $105.35 million.

Several equities research analysts have recently issued reports on NXTM shares. ValuEngine raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, October 12th. BidaskClub raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, Zacks Investment Research raised shares of NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th.

Shares of NXTM stock traded up $0.02 during trading hours on Monday, hitting $29.03. 813,700 shares of the company were exchanged, compared to its average volume of 504,304. NxStage Medical has a 52 week low of $22.70 and a 52 week high of $29.19. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -131.95 and a beta of -0.05.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its position in NxStage Medical by 10.5% in the second quarter. BlackRock Inc. now owns 5,289,606 shares of the medical device company’s stock valued at $147,581,000 after purchasing an additional 501,922 shares in the last quarter. Alpine Associates Management Inc. grew its position in NxStage Medical by 0.9% in the second quarter. Alpine Associates Management Inc. now owns 3,326,982 shares of the medical device company’s stock valued at $93,087,000 after purchasing an additional 30,300 shares in the last quarter. Water Island Capital LLC grew its position in NxStage Medical by 12.6% in the second quarter. Water Island Capital LLC now owns 1,334,420 shares of the medical device company’s stock valued at $37,230,000 after purchasing an additional 149,713 shares in the last quarter. JPMorgan Chase & Co. grew its position in NxStage Medical by 56.3% in the third quarter. JPMorgan Chase & Co. now owns 1,187,250 shares of the medical device company’s stock valued at $33,113,000 after purchasing an additional 427,745 shares in the last quarter. Finally, Northern Trust Corp grew its position in NxStage Medical by 3.0% in the second quarter. Northern Trust Corp now owns 885,227 shares of the medical device company’s stock valued at $24,697,000 after purchasing an additional 25,633 shares in the last quarter. 83.15% of the stock is owned by institutional investors.

NxStage Medical Company Profile

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Recommended Story: Rule of 72

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply